Skip to main content
. 2020 Jun 24;11(1):156–180. doi: 10.1016/j.apsb.2020.06.003

Figure 8.

Figure 8

In vivo antitumor efficacy of compound 19d in the MDA-MB-468 tumor xenograft model and the MCF-7 tumor xenograft model. (A) Tumor volume changes, average body weights and tumor weights following the treatment of 19d at oral doses of 20, 40 and 80 mg/kg in the MDA-MB-468 tumor xenograft model. (B) Tumor volume changes, average body weight and tumor weight following the treatment of 19d at oral doses of 20, 40 and 80 mg/kg in the MCF-7 tumor xenograft model. (C) Immunohistochemical staining of PARP1 and BRD4 in the MDA-MB-468 tumor tissues from 40 mg/kg of 19d-treated mice and vehicle groups (200 ×), respectively.